![Page 1: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/1.jpg)
BROSYM
Cefoperazone/sulbactam: empirical use for nosocomial infections
:
![Page 2: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/2.jpg)
Diversity of nosocomial pathogens
2
醫學中心醫學中心醫學中心醫學中心
區域醫院區域醫院區域醫院區域醫院
台灣院內感染監視資訊系統(TNIS)(TNIS)(TNIS)(TNIS)
![Page 3: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/3.jpg)
Regimens for nosocomial infections
� Broad-spectrum antibiotics� Ceftazidime, Cefepime
� Piperacillin/tazobactam� Carbapenems
� Quinolones
+/-� Anti-MRSA
+/-� Anti-anaerobes
3
![Page 4: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/4.jpg)
Current empirical therapy for nosocomial infection
4
A.b.
Current empiricalbroad spectrum antibiotic
P.a.
P.a. S.a.S.a.
Anaerobes
Anaerobes
Anaerobes
A.b.A.b.
K.p.
K.p.
![Page 5: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/5.jpg)
Carbapenem-resistant Acinetobacter baumannii: alway s multidrug resistant
5台灣院內感染監視資訊系統(TNIS)(TNIS)(TNIS)(TNIS)
![Page 6: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/6.jpg)
Inappropriate therapy results in grave outcome for A. baumannii
6
Lee YT, Chen TL, et al. CID 2012:55 209-215
![Page 7: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/7.jpg)
Outline
� Background information of Brosym � Microbiology spectrum� Approved indications and guideline� Potential side effects.
7
![Page 8: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/8.jpg)
Product introduction
� 產品名:博益欣注射劑 Brosym for Injection� 成 分: Cefoperazone 500mg/Sulbactam 500mg� 規 格: 1g/vial (效價)� 類 別: 新複方新藥
� 健保價: 297元/vial
� 同成分同劑型藥品他國上市現況:� 複方製劑( Cefoperazone / Sulbactam ):
� 十大先進國:日本(1986年)
8
![Page 9: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/9.jpg)
The mechanism of Brosym
� Cefoperazone ( CPZ)� 3rd cephalosporin.� Inhibition of bacterial cell wall synthesis through binding on PBP. � Spectrum cover G(+) and G(-),including Pseudomonas。
� Sulbactam ( SUL)� β-lactamase inhibitor.� Intrinsic activity against Acinetobacter, Bacteroides spp.
9
![Page 10: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/10.jpg)
Antimicrobial spectrum of CPZ/SUL
10
Antimicrobial spectrum Summary of Spectrum
G(+) Staphylococcus spp. Most G(+),except MRSA, Enterococcus
G(-)
Including:E. coliCitrobacter spp.Klebsiella spp.Enterobacter spp.Serratia,Proteus spp.P. aeruginosaH. InfluenzaeAcinetobacter spp.
All important G(-), including P. aeruginosa and A. baumannii
(Except Stenotrophomonas maltophila)
Anaerobes Bacteroides All important anaerobes
(Except Clostridium species, but Clostridium perfringens is ok)
10
![Page 11: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/11.jpg)
11
Pathogens* NCPZ CPZ/SUL (1:1)
MIC50 MIC90 S (%) I (%) R (%) MIC50 MIC90 S (%) I (%) R (%)
Group A Streptococcus 39 0.125 0.25 100 0 0 0.25 0.5 100 0 0
Group B Streptococcus 102 0.25 0.5 100 0 0 0.25 0.5 100 0 0
MSSA 242 4 4 100 0 0 2 4 100 0 0
Streptococcus pneumoniae 93 2 8 100 0 0 2 8 100 0 0
Chiu CH et al. Unpublished data
Susceptibilities of some important Gram (+) pathogens: 2012
11
�Isolates from NTUH, TVGH, CGMH, CMH, ChMH
![Page 12: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/12.jpg)
12
Pathogens* NCPZ CPZ/SUL
MIC50 MIC90 S (%) I (%) R (%) MIC50 MIC90 S (%) I (%) R (%)
E. coli 250 16 128 46.4 24.8 28.8 2 16 88 9.2 2.8
K. pneumoniae 231 2 128 64.9 7.4 27.7 0.5 32 84.8 9.1 6.1
P. mirabilis 174 2 128 76.2 10.8 13.1 1 8 95.4 3.5 0
S. marcescens 130 4 64 70.7 13.8 15.3 2 8 90 9.2 0.8
E. cloacae 178 2 128 76.4 7.3 16.3 1 16 84.8 14.6 0.6
Other Enterobacteriaceae 52 16 128 34.6 44.2 21.2 4 16 84.6 15.4 0
A. baumannii 375 >128 >128 0.27 5.1 94.7 8 64 71.2 17.6 11.2
P. aeruginosa 178 8 128 75.8 6.7 17.4 8 32 81.5 12.1 6.2
S. maltophilia 87 128 >128 5.8 4.6 89.7 64 128 20.7 12.6 66.7
Salmonella spp. 149 4 64 75.2 6.0 18.8 2 8 99.3 0.7 0
Chiu CH et al. Unpublished data
Susceptibilities of some important Gram (-) pathogens: 2012
12
�Isolates from NTUH, TVGH, CGMH, CMH, ChMH
![Page 13: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/13.jpg)
Susceptibilities of some important Gram (-) pathogens: 2009
13
PIP/TAZ CPZ CPZ/SUL (1:1)
PIP/TAZ CPZ CPZ/SUL (1:1)
Pathogens N MIC90 (mg/L) Resistant (%)
ESBL (-) K. pneumoniae
50 16 64 4 2 10 0
ESBL (+) K. pneumoniae
50 64 >128 32 6 76 8
E. coli 50 32 16 8 2 4 2
E. cloacae 50 64 >128 32 6 36 2
S. marcescens 50 128 >128 32 12 42 6
P. aeruginosa 50 64 64 32 4 14 2
Imipenem-susceptibleA. baumannii
50 128 >128 16 10 64 0
Imipenem-resistant A. baumannii
50 >128 >128 32 76 100 8
S. maltophilia 50 >128 >128 32 96 64 30
Kuo HY et al. NEW MICROBIOLOGICA 2009; 32: 49-55
![Page 14: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/14.jpg)
CPZ/SUL has lower resistant rate against A.baumannii than Amp/SUL
14
ββββ-lactam/ββββ-lactamase Inhibitor Combinations against Acinetobacter baumannii
Resistant No. (%)
Ampicillin/sulbactam ( 2:1)
Cefoperazone/sulbactam ( 2:1)
Cefoperazone/sulbactam ( 1:1)
A. baumannii( IMP-susceptible )(N=68)
16 (23.5) 2 (2.9) 2 (2.9)
A. baumannii( IMP-resistant )(N=30)
9 (30) 5 (16.6) 3 (10)
1. Agar dilution2. Wang FD et al. Int J Antimicrob Agents 2004; 23: 590-595
![Page 15: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/15.jpg)
15Journal of Clinical and Diagnostic Research. 2013 February, Vol-7(2): 224-228
![Page 16: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/16.jpg)
CFP/SUL has low resistant rate in EU
16
# #
# Resistant rate >70%
![Page 17: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/17.jpg)
Outline
� Background information of Brosym � Microbiology spectrum� Approved indications and guideline� Potential side effects.
17
![Page 18: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/18.jpg)
Approved indications and dosage
� Upper and lower respiratory tract infections.
� Upper and lower urinary tract infections.
� Peritonitis , cholecystitis, cholangitis and other intra-abdominal infections.
� Pelvic inflammatory disease, endometritis, and other genitalia tract infection.
� Trauma, burn, surgical-site-associated infections.
18
Population Suggested dosage
Adult •Severe infection: 4g, q12h
Pediatric • Severe infection:160mg/kg/day,• divided into 2-4 times /day
![Page 19: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/19.jpg)
Design of TW phase III registration trial
19
hospital-acquired pneumonia (HAP) and healthcare-associated pneumonia (HCAP)
• Comparative
• Randomized (1:1)
� 12 medical centers: 北榮、三總、雙和、萬芳、林長、、中山、奇美、成大、高長、高醫、高榮、義大
� 60位試驗(總/協同)主持人
試驗人數
Phase III study
Registration trial
Non-inferiority
designed
cefoperazone/ sulbactam: 4g q12h (8瓶/day)
cefepime ( Maxipime): 2g q12h ( 8瓶/day )
C+S cefepime total
Safety 79 87 166
Evaluable 66 81 147
19
![Page 20: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/20.jpg)
Phase III registration trial ( TW)
20
Patient Population Hospital-acquired pneumonia and Healthcare-associated pneumonia
Patient no. 66 81
Regimens CPZ/SUL :4g q12h Cefepime: 2g q12h
Duration (d) of therapy 10.0± 2.9 10.6±3.0
Clinical response rate 81.8% 79%
![Page 21: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/21.jpg)
Safety results in Taiwan pivotal trial
21
CPZ/SBT (N=79) Cefepime (N=87)消化器官消化器官消化器官消化器官
腹瀉腹瀉腹瀉腹瀉 5 (6.3%) 2 (2.3%)嘔吐嘔吐嘔吐嘔吐 1 (1.3%) 1 (1.1%)便秘便秘便秘便秘 1 (1.3%) 0 (0%)
檢驗數值檢驗數值檢驗數值檢驗數值
AST、、、、ALT增加增加增加增加 2 (2.5%) 3 (3.4%)ALK-P增加增加增加增加 0 (0%) 1 (1.1%)PT、、、、APTT延長延長延長延長 2 (2.5%) 0 (0%)Eosinophil 增加增加增加增加 2 (2.5%) 0 (0%)血小板減少血小板減少血小板減少血小板減少 1 (1.3%) 0 (0%)高血鉀高血鉀高血鉀高血鉀 1 (1.3%) 0 (0%)低血鉀低血鉀低血鉀低血鉀 1 (1.3%) 1 (1.1%)
血液血液血液血液
貧血貧血貧血貧血 1 (1.3%) 0 (0%)其他其他其他其他
肝炎肝炎肝炎肝炎 0 (0%) 2 (2.3%)血尿血尿血尿血尿 1 (1.3%) 0 (0%)蛋白尿蛋白尿蛋白尿蛋白尿 0 (0%) 1 (1.1%)發汗發汗發汗發汗 0 (0%) 1 (1.1%)21
![Page 22: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/22.jpg)
Summary of the Phase III bridging study
� The efficacy of cefoperazone/sulbactam was not inferior to cefepime in patients with HAP and HCAP.
� Cefoperazone/sulbactam was safe for patients with HAP and HCAP.
2222
![Page 23: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/23.jpg)
Treatment recommendations for hospital acquired pneumonia (HAP) in Asia
Initial empirical antibiotic treatment for late ons et HAP
Potential pathogens Recommended antibiotic regimen
Streptococcus pneumoniaeHaemophilus influenzaeMSSAAntibiotic-sensitive enteric Gram-negative bacilli::::Escherichia coliEnterobacter speciesProteus speciesSerratia marcescens
MDR pathogensPseudomonas aeruginosaKlebsiella pneumoniae (ESBL)*Acinetobacter species*
Antipseudomonal cephalosporin (cefepime, ceftazidime)orAntipseudomonal carbepene (imipenem or meropenem)orβ-lactam/β-lactamase inhibitor (piperacillin-tazobactam)orCefoperazone/sulbactam+ Fluoroquinolone (ciprofloxacin or levofloxacin)orAminoglycoside (amikacin, gentamicin, or tobramycin)
Ampicillin/sulbactam (if sulbactam is not available)+ Fluoroquinolone (ciprofloxacin) or aminoglycoside
MRSA +/- linezolid or vancomycin†
Legionella pneumophila +/- azithromycin or fluoroquinolone&
23
Modified from Am J Infect Control 2008, Vol. 36 No. 4 Supp. 2, s83-92
23
![Page 24: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/24.jpg)
Treatment recommendations for HAP in Asia
24
Am J Infect Control 2008;36:S83-92
![Page 25: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/25.jpg)
對CRAB建議SUL劑量為≧6g/d
� Sulbactam: time-dependent
� i.v. 1g, T1/2~1hr, peak concentration 43mg/L
� 4g/day is inadequate to cover CRAB with MIC90: 32mg/L
� ≧6g/d of sulbactam is recommended
25
IJAA ;2013:41:393–401
25
![Page 26: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/26.jpg)
CRAB感染病人的Brosym使用劑量
� 文獻顯示sulbactam須使用高劑量
� A case report of sulbactam 8g/day for MDR-Ab meningitis. No AE. Pharmacotherapy. 2002 Apr;22(4):527-32.
� Randomized study, sulbactam 9 or 12g/day for MDR-Ab VAP. No major AE. Scand J Infect Dis.2007;39(1):38-43.
� A prospective study, sulbactam 9g/day for MDR-Ab VAP. Comparable safe. Journal of Infection (2008) 56, 432-436.
• CCr>.60: 3g tid ( 9g/day)
• CCr 30~60: 2.25g tid ( 6.75g/day)
• CCr 7~30: 1.5g bid ( 3g/day)
� Brosym劑量 4g q8h ( 其中sulbactam為6g/day)
26
![Page 27: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/27.jpg)
CPZ/SUL + colistin has synergistic effect on MDR-Ab
27
CPS: cefoperazon/ sulbactamCO: colistinRI: rifampicinIR: imipenem
ScienceAsia 40 (2014): 28–34
![Page 28: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/28.jpg)
Colistin-based treatment for XDR-Ab pneumonia
CL � Inhaled colistin 40mg q6h� IV colistin 300mg loading followed by 150mg q12h
SB Sulbactam 6g/day (cefoperazone/sulbactam)
TC Tigecycline 100mg loading followed by 50mg q12h
CBHigh dose carbapenem prolonged infusion�Imipenem 1g over 3hr q8h�Meropenem 1g over 3hr q8h�Doripenem 1g over 4hr q8h
28International Journal of Antimicrobial Agents 43 2014; 378–382
![Page 29: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/29.jpg)
Colistin-based treatment for XDR-Ab pneumonia
29
CL+SB: 65%
CL+CB: 60%
CL+TC: 53%
International Journal of Antimicrobial Agents 43 2014; 378–382
![Page 30: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/30.jpg)
Proposed guidelines for IAI in Asia
30
International Journal of Antimicrobial Agents 30 (2007) 129–133
![Page 31: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/31.jpg)
RCT for Intra-abdominal Infection
31
• CPZ/SUL (2–8 g/day) • CAZ (2–6 g/day)-AMK (15 mg/kg/day)-MTZ
(500 mg q8h).
MASCOT Study Group et al. SURGICAL INFECTIONS 2008; 9, 367-376
![Page 32: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/32.jpg)
32
Overall results (IAI)
MASCOT Study Group et al. SURGICAL INFECTIONS 2008; 9, 367-376
CPZ/SUL CAZ+AMK+MTZ
Clinical outcome at 30-day follow up (CEE) 125/136 (91.9%) 108/132 (81.8%)
Clinical outcome at 30-day follow up (MITT) 134/154 (89.3%) 118/152 (79.2%)
Microbiologic outcomes (MEE) 65/71 (92.9%) 52/66 (80.0%)
Treatment-related adverse events 6.5% 16.4%
Discontinuations 12.3% 22.4%
![Page 33: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/33.jpg)
European guidelines for empirical antibacterial the rapy for febrile neutropenic patients in the era of growing resistance
33Haematologica 2013; 98: 1826-1835
![Page 34: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/34.jpg)
34
European guidelines for empirical antibacterial the rapy for febrile neutropenic patients in the era of growing resistance
Haematologica 2013; 98: 1826-1835
![Page 35: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/35.jpg)
Outline
� Background information of Brosym � Microbiology spectrum� Approved indications and guideline� Potential side effects.
35
![Page 36: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/36.jpg)
1. 改變會合成Vit. K的腸道菌
2. N-MTT (N-methylthiotetrazole) side chain: coumadin effect.
�Risks: malnutrition, hepatic and renal dysfunction, older age, and severity of illness, febrile neutropenia patient.
�Management:� 預防: 建議監測PT � 緊急: Vitamin K 10mg iv, FFP ( fresh frozen plasma)
Potential prothrombin time (PT) prolongation
![Page 37: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/37.jpg)
37
� A teaching hospital in Philadelphia from Feb. 1983 to Mar. 1986.
Incidence of hypoprothrombinemia & bleeding
Cefoperazone (374)
Ceftizoxime or cefotaxime (497)
Ceftazidime(476)
PT prolonged (>5s)
12.3% 5.8% 5.8%
Adjusted OR (95% CIs) = 3.6 (1.7-7.4) and 3.8 (1.8-7.8).
Risk of bleeding
Adjusted OR (95% CIs) = 1.1 (0.8-1.4) and 0.9 (0.6-1.2).
Strom BL et al. Pharmacoepidemiol drug saf 1999;8:81-94.
![Page 38: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/38.jpg)
Avoid use of Brosym
� Liver function Child C� sepsis with DIC、
� Receiving heparin ( ex. Some hemodialysis patient)
� Taking warfarin:置換心臟機械瓣膜、心房顫動,深部靜脈栓塞的病人
38
![Page 39: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/39.jpg)
RCT for neutropenic fever
� Brosym 4g q8h is suggested for neutropenic fever patient.39
Eur. J. Clin. Microbiol. Infect. Dis., 1996, 15:625-634.
Clinical Infectious Diseases 1998;26:576–83.
Patient no. 174 175 101 102
›ANC <100/mm3 (%) 54% 54% 74% 82%
Regimens CPZ/SUL :2/1g q8h Imipenem:500mg, q6h
CPZ/SUL: 4/2g q12h
Imipenem:500 mg, q6h
Duration (d) of therapy NA NA 12 (3–69) 14 (3–50)
Clinical response rate 74% 73% 88 % 81%
Adverse events Diarrhea: 0.4%Nausea/vomiting: 0C. difficile infection:0
0%5.3%5%
Diarrhea: 31 (31%)
15 (15%)
Possible coagulopathy NA NA 10 (10%) 5 (5%)
hemorrhage NA NA 0 0
Note 10mg Vit. K once per week. Both, vancomycin 1g q12h
Both, 10mg Vit. K pre-therapy, and once per week.
![Page 40: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/40.jpg)
Brosym PK parameters
CPZ SUL
T1/2 1.7hr ~2hr ~1hr
protein binding ~85% ~38%
代謝 幾乎不被代謝 幾乎不被代謝
排除75% 肝25% 腎 幾乎全為腎
40
![Page 41: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/41.jpg)
腎功能不佳時cefoperazone/sulbactam依文獻推論劑量(CPZ/SUL= 1:1)
1. Brosym 仿單
2. Pharmacotherapy. 2002; Apr 22 (4):527-32.
3. Scand J Infect Dis.2007;39(1):38-43.
4. Journal of Infection 2008; 56: 432-436.
5. Eur. J. Clin. Microbiol. Infect. Dis. 1996;15:625-634
6. Clinical Infectious Diseases 1998;26:576–83.
7. 2012 Guide to antimicrobial therapy in adult ICU Malaysian Society in Intensive Care
肌酸酐廓清率肌酸酐廓清率肌酸酐廓清率肌酸酐廓清率
(CCr,,,,mL/min)
CPZ/SUL參考劑量參考劑量參考劑量參考劑量
( other than CRAB and FN)
CPZ/SUL參考劑量參考劑量參考劑量參考劑量
( For CRAB and FN)
>30 4g, q12h1 4g, q8h 2-6
15~ 30 4g, q12h7 4g, q12h7
4141
CCr<15: 因此族群會有洗腎患者,當洗腎患者接受iv. Heparin後再使用Brosym會增加PT副作用,而各醫院對於洗腎患者是否IV給予heparin之操作不同。,因此為避免困擾,不建議CCr<15之患者使用Brosym。
![Page 42: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/42.jpg)
Drug interaction
� 利尿劑(furosemide): 與類似化合物(其他furosemide系藥劑)併用時會增強腎功能障礙。
� 酒精:飲酒有時因Disulfiram作用,會有顏部潮紅、噁心、心悸亢進、多汗、頭痛等發生,因此使用期間和使用過後至少一週內不能飲酒
42
![Page 43: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/43.jpg)
Summary of Brosym
� Broad antimicrobial spectrum which can cover most of the nosocomial pathogens including P. a. and A. b.
� Empirical therapy for nosocomial infection
� Dosage: Brosym 4g q12h.
� For CRAB infection or febrile neutropenia: 4g q8h is suggested.
� Multiple indications. � 上、下呼吸道感染、
� 上、下泌尿道感染、
� 腹膜炎、膽囊炎、膽管炎及其它腹腔內感染、
� 骨盆發炎、子宮內膜炎及其它生殖道感染、
� 創傷燙傷、手術後之二次感染。
43
![Page 44: 20160120-Brosym 2016 s · February, Vol-7(2): 224-228. CFP/SUL has low resistant rate in EU 16 # # # Resistant rate >70%. Outline Background information of Brosym Microbiology spectrum](https://reader033.vdocuments.pub/reader033/viewer/2022041416/5e1bb8e270e96836ca3b59fd/html5/thumbnails/44.jpg)
THANK YOU!